Management of Immunotherapy-Related Toxicities. Version 1.2019

被引：435

作者：

Thompson, John A. ^{[1
]}

Schneider, Bryan J. ^{[2
]}

Brahmer, Julie ^{[3
]}

Andrews, Stephanie ^{[4
]}

Armand, Philippe ^{[5
]}

Bhatia, Shailender ^{[1
]}

Budde, Lihua E. ^{[6
]}

Costa, Luciano ^{[7
]}

Davies, Marianne ^{[8
]}

Dunnington, David

Ernstoff, Marc S. ^{[9
]}

Frigault, Matthew ^{[10
]}

Hoffner, Brianna ^{[11
]}

Hoimes, Christopher J. ^{[12
,13
]}

Lacouture, Mario ^{[14
]}

Locke, Frederick ^{[4
]}

Lunning, Matthew ^{[15
]}

Mohindra, Nisha A. ^{[16
]}

Naidoo, Jarushka ^{[3
]}

Olszanski, Anthony J. ^{[17
]}

Oluwole, Olalekan ^{[18
]}

Patel, Sandip P. ^{[19
]}

Reddy, Sunil ^{[20
]}

Ryder, Mabel ^{[21
]}

Santomasso, Bianca ^{[14
]}

Shofer, Scott ^{[22
]}

Sosman, Jeffrey A. ^{[16
]}

Wahidi, Momen ^{[22
]}

Wang, Yinghong ^{[23
]}

Johnson-Chilla, Alyse ^{[24
]}

Scavone, Jillian L. ^{[24
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[2] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[6] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[7] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA

[8] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[9] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[11] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[12] Univ Hosp Seidman Canc Ctr, Case Comprehens Ctr, Cleveland, OH USA

[13] Cleveland Clin Taussig Canc Inst, Cleveland, OH USA

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[16] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[17] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[18] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[19] UC San Diego Moores Canc Ctr, San Diego, CA USA

[20] Stanford Canc Inst, Stanford, CA USA

[21] Mayo Clin, Ctr Canc, Rochester, MI USA

[22] Duke Canc Inst, Durham, NC USA

[23] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[24] Natl Comprehens Canc Network, Plymouth Meeting, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 03期

关键词：

IMMUNE CHECKPOINT INHIBITORS; ACUTE INTERSTITIAL NEPHRITIS; NIVOLUMAB PLUS IPILIMUMAB; CELL LUNG-CANCER; INTRAVENOUS IMMUNOGLOBULIN THERAPY; CUTANEOUS ADVERSE EVENTS; STAGE-III MELANOMA; PROGRAMMED DEATH 1; MYCOPHENOLATE-MOFETIL; OPEN-LABEL;

D O I：

10.6004/jnccn.2019.0013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

引用

页码：255 / 288

页数：34

共 204 条

[1] Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review [J].

Abdel-Rahman, Omar ;

Oweira, Hani ;

Petrausch, Ulf ;

Helbling, Daniel ;

Schmidt, Jan ;

Mannhart, Meinrad ;

Mehrabi, Arianeb ;

Schoeb, Othmar ;

Giryes, Anwar .

EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) :387-394

[2] Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review [J].

Abdel-Wahab, Noha ;

Shah, Mohsin ;

Lopez-Olivo, Maria A. ;

Suarez-Almazor, Maria E. .

ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) :121-+

[3] Therapeutic advances in myositis [J].

Aggarwal, Rohit ;

Oddis, Chester V. .

CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (06) :635-641

[4] Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors [J].

Alessandrino, F. ;

Tirumani, S. H. ;

Krajewski, K. M. ;

Shinagare, A. B. ;

Jagannathan, J. P. ;

Ramaiya, N. H. ;

Di Salvo, D. N. .

CLINICAL RADIOLOGY, 2017, 72 (07) :521-533

[5] Multimodality imaging of endocrine immune related adverse events: a primer for radiologists [J].

Alessandrino, Francesco ;

Shah, Hina J. ;

Ramaiya, Nikhil H. .

CLINICAL IMAGING, 2018, 50 :96-103

[6] Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection [J].

Allison, AC ;

Eugui, EM .

TRANSPLANTATION, 2005, 80 (02) :S181-S190

[7] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].

Alsaab, Hashem O. ;

Sau, Samaresh ;

Alzhrani, Rami ;

Tatiparti, Katyayani ;

Bhise, Ketki ;

Kashaw, Sushil K. ;

Iyer, Arun K. .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[8] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[9] Ocular and orbital side-effects of checkpoint inhibitors: a review article [J].

Antoun, Joelle ;

Titah, Cherif ;

Cochereau, Isabelle .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :288-294

[10] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

← 1 2 3 4 5 6 7 8 9 10 →